Rhythm Pharmaceuticals (RYTM) Cash & Current Investments (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Cash & Current Investments data on file, last reported at $340.6 million in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $340.6 million, up 8.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $340.6 million (up 8.31% YoY), and the FY2025 annual result was $388.9 million, up 21.33% from the prior year.
• Cash & Current Investments fell to $340.6 million in Q1 2026 per RYTM's latest filing, from $388.9 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $416.7 million in Q3 2025 and troughed at $201.7 million in Q1 2024.
• A 5-year average of $304.5 million and a median of $299.6 million in 2023 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2022 and 2025: Cash & Current Investments sank 40.43% in 2022, then surged 55.95% in 2025.
• A 5-year view of Cash & Current Investments shows it stood at $333.6 million in 2022, then declined by 17.22% to $276.2 million in 2023, then advanced by 16.07% to $320.6 million in 2024, then advanced by 21.33% to $388.9 million in 2025, then declined by 12.42% to $340.6 million in 2026.
• Business Quant data shows RYTM's Cash & Current Investments at $340.6 million in Q1 2026, $388.9 million in Q4 2025, and $416.7 million in Q3 2025.